{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:10:08Z","timestamp":1776125408567,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012171","name":"Ontario Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioorg.2026.109807","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:44:36Z","timestamp":1774583076000},"page":"109807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Urea-based lysophosphatidic acid receptor 1 antagonists as potential migrastatics for triple-negative breast cancer"],"prefix":"10.1016","volume":"175","author":[{"given":"Wenjie","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr A.K.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillem","family":"Dayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin M.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J.","family":"Lees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rithwik","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinqiang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109807_bb0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109807_bb0010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clon.2011.03.013","article-title":"Metastatic triple-negative breast cancer","volume":"23","author":"Rakha","year":"2011","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109807_bb0015","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","article-title":"Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy","volume":"27","author":"Pivot","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109807_bb0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-010-0824-0","article-title":"Efficacy of ixabepilone in ER\/PR\/HER2-negative (triple-negative) breast cancer","volume":"121","author":"Perez","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bioorg.2026.109807_bb0025","doi-asserted-by":"crossref","first-page":"v859","DOI":"10.1093\/annonc\/mdz394.010","article-title":"KEYNOTE-119: phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)","volume":"50","author":"Cort\u00e9s","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109807_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105386","article-title":"The development of modulators for lysophosphatidic acid receptors: a comprehensive review","volume":"117","author":"Liu","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109807_bb0035","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/1541-7786.MCR-08-0578","article-title":"Beta-arrestin\/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells","volume":"7","author":"Li","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109807_bb0040","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1172\/JCI200422123","article-title":"Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer","volume":"114","author":"Boucharaba","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2026.109807_bb0045","doi-asserted-by":"crossref","first-page":"9643","DOI":"10.1073\/pnas.0600979103","article-title":"The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases","volume":"103","author":"Boucharaba","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.109807_bb0050","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3892\/ijo.2011.1309","article-title":"Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis","volume":"40","author":"David","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2026.109807_bb0055","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/jnci\/djs319","article-title":"Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer","volume":"104","author":"Marshall","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2026.109807_bb0060","article-title":"Lysophosphatidic acid receptor 1 (LPA1) antagonists as potential Migrastatics for triple negative breast cancer","volume":"19","author":"Liu","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.109807_bb0065","doi-asserted-by":"crossref","first-page":"15549","DOI":"10.1021\/acs.jmedchem.1c01256","article-title":"Discovery of an Oxycyclohexyl acid lysophosphatidic acid receptor 1 (LPA1) antagonist BMS-986278 for the treatment of pulmonary fibrotic diseases","volume":"64","author":"Cheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109807_bb0070","doi-asserted-by":"crossref","first-page":"7920","DOI":"10.1021\/jm301022v","article-title":"Discovery of highly selective and orally active lysophosphatidic acid Receptor-1 antagonists with potent activity on human lung fibroblasts","volume":"55","author":"Qian","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109807_bb0075","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1124\/mol.64.4.994","article-title":"Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors","volume":"64","author":"Ohta","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109807_bb0080","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/j.1476-5381.2010.00828.x","article-title":"A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model","volume":"160","author":"Swaney","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109807_bb0085","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1126\/science.aaz0326","article-title":"Molecular mechanism of biased signaling in a prototypical G protein-coupled receptor","volume":"367","author":"Suomivuori","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109807_bb0090","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.tips.2025.10.008","article-title":"Elucidating biased signaling in class a GPCRs","volume":"46","author":"Xu","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2026.109807_bb0095","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.cell.2015.06.002","article-title":"Crystal structure of antagonist bound human lysophosphatidic acid receptor 1","volume":"161","author":"Chrencik","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109807_bb0100","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109807_bb0105","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3816\/CBC.2008.n.025","article-title":"Metastatic breast cancer: the treatment challenge","volume":"8","author":"Jones","year":"2008","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bioorg.2026.109807_bb0110","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/annonc\/mdp492","article-title":"Triple-negative breast cancer--current status and future directions","volume":"20","author":"Gluz","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109807_bb0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.trecan.2017.04.008","article-title":"Migrastatics\u2014anti-metastatic and anti-invasion drugs: promises and challenges","volume":"3","author":"Gandalovi\u010dov\u00e1","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bioorg.2026.109807_bb0120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.trecan.2023.01.001","article-title":"Engine shutdown: migrastatic strategies and prevention of metastases","volume":"9","author":"Raudensk\u00e1","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bioorg.2026.109807_bb0125","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.trecan.2019.10.011","article-title":"Migrastatics: redirecting R&D in solid cancer towards metastasis?","volume":"5","author":"Rosel","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bioorg.2026.109807_bb0130","series-title":"FDA Approves New Treatment for a Certain Type of Prostate Cancer Using Novel Clinical Trial Endpoint","author":"U.S. Food & Drug Administration","year":"2018"},{"key":"10.1016\/j.bioorg.2026.109807_bb0135","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/sj.bjc.6605588","article-title":"Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression","volume":"102","author":"Panupinthu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109807_bb0140","doi-asserted-by":"crossref","first-page":"17634","DOI":"10.1074\/jbc.M313927200","article-title":"Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1","volume":"279","author":"Hama","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109807_bb0145","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1111\/bph.14362","article-title":"Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis","volume":"175","author":"Leblanc","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109807_bb0150","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein\u2013ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"Forli","year":"2016","journal-title":"Nat. Protoc."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826003433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826003433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:24:07Z","timestamp":1776122647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826003433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"alternative-id":["S0045206826003433"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109807","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urea-based lysophosphatidic acid receptor 1 antagonists as potential migrastatics for triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109807"}}